A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents

Babapulle, Mohan; Joseph, Lawrence; Bélisle, Patrick; Brophy, James M.; Eisenberg, Mark J.

doi:10.1016/s0140-6736(04)16850-5

Cited by 585 publications

(299 citation statements)

References 41 publications

Supporting

Mentioning

282

Contrasting

Unclassified

Order By: Relevance

“…Findings from the present study reinforce the concept that DMSO is an interesting alternative for the coating of DES where currently employed drugs do not completely address the risks of stent thrombosis [4,5,14,15,17,20,31,34] and, in addition, were shown to induce the expression of TF [29,32,38].…”

Section: Discussionsupporting

confidence: 71%

“…Even though coronary bare metal stents (BMS) and drug-eluting stent (DES) implantation greatly improved prognosis of ACS patients, acute and sub-acute stent thrombosis still remain a serious concern [4,5,14,15,17,20,31,34]. In line with this, we recently showed that drugs released from DES enhance tissue factor (TF), a key trigger for thrombosis and thus could play a paradoxical role in eliciting stent thrombosis [29,32].…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

Asmis

Tanner

Sudano

et al. 2010

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 71%

Section: Introductionmentioning

confidence: 96%

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

Asmis

Tanner

Sudano

et al. 2010

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…6 In contrast, some randomized DES trials report BMS reintervention rates as high as 22.9%. 2 We used an expanded definition of "target lesion" to include anatomy adjacent to the stented segment because adjacent segment treatment may have been recorded due to inconsistent coding of arterial segments or lesions that straddle two or more segments. This anatomically generous definition reduced our risk of underestimating stent-related restenosis due to segment coding inconsistencies.…”

Section: Discussionmentioning

confidence: 99%

Bare-metal stent outcomes in an unselected patient population

Yock

Isbill²,

King

2006

Clin Cardiol

View full text Add to dashboard Cite

SummaryBackground: Randomized trials have shown that drug-eluting stents (DES) substantially reduce in-stent restenosis compared with bare-metal stents (BMS).Hypothesis: Revascularization event rates related to BMS restenosis may be higher in the trials setting than in real-world experience, calling into question the extent of benefit possible with widespread DES use in regular practice.Methods: Between December 1998 and March 2003, 17,102 patients with BMS registered in the Goodroe Healthcare Solutions Data Warehouse met the inclusion criteria for this retrospective study of catheterization laboratory data. We examined the database for evidence of diagnostic angiography or percutaneous coronary intervention (PCI) readmission within 1 year after stenting.Results: Repeat PCI was documented for 2,070 patients, and 232 were referred for coronary artery bypass graft surgery (CABG)-in sum, 13.5% of the cohort. Stented region revascularization was observed in 8.4%: 1,350 patients underwent subsequent PCI, and 84 of the patients referred for CABG had in-stent lesion recurrence. Only 1,207 (7.1%) patients required stent-related PCI after 30 days, the time frame consistent with restenosis.Conclusions: In this "real-world" series, reintervention of a stented region after the first follow-up month was documented in fewer than 8% of patients in a large cohort that had received BMS. The rate of clinical events potentially related to BMS instent restenosis in this large, unselected patient population is substantially lower than that in the control arms of some DES trials. The incremental benefit of widespread conversion from

show abstract

“…The six-month rate of restenosis after PCI remains at approximately 9%, despite the advent of drug-eluting stents (39). Evaluation of resten osis is usually performed with CCA.…”

Section: Assessment Of In-stent Restenosis Using Mdctmentioning

confidence: 99%

Transitioning from 16-slice to 64-slice multidetector computed tomography for the assessment of coronary artery disease: Are we really making progress?

Khan

Rawal

Eisenberg

2009

Canadian Journal of Cardiology

View full text Add to dashboard Cite

A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents

Cited by 585 publications

References 41 publications

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

Bare-metal stent outcomes in an unselected patient population

Transitioning from 16-slice to 64-slice multidetector computed tomography for the assessment of coronary artery disease: Are we really making progress?

Contact Info

Product

Resources

About